The Chronic Lymphocytic Leukemia (CLL) Channel

Zanubrutinib receives FDA approval for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma

Zanubrutinib was approved by the Food and Drug Administration (FDA) on the 19th of January 2023, for the treatment of…

ASH late-breaking abstract rundown

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

VJSocial Media Masterclass – Social Media Strategy

Learn how to build a social media strategy effectively and appropriately alongside your clinical practice. Independent medical support by Janssen…

VJSocial Media Masterclass – Engagement on Twitter

Learn how to engage on Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals

Highlights in lymphoid malignancies from EHA 2022

VJHemOnc is excited to bring you the latest research updates in lymphoid malignancies from the EHA 2022 Congress, which took…

Genomic testing and clinical decision making in CLL

Learn about the importance of performing genomic testing in CLL and how this impacts diagnosis, prognosis and treatment decisions.

VJSocial Media Masterclass

Learn how to use Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals

BTK inhibitors for B-cell malignancies: managing and improving class-driven adverse events

Bruton’s tyrosine kinase (BTK) inhibitors fulfill an increasingly important role in the treatment of patients with B-cell malignancies including chronic…

Non-covalent BTK inhibitor LOXO-305 shows promising results in advanced B-cell malignancies

Bruton’s tyrosine kinase (BTK) plays an essential role in the B-cell antigen receptor signaling pathway and is required for the…

The VJ Sessions:
Roundtable discussions with leading experts in hemonc

VJHemOnc brings you roundtable discussions with leading hematological experts in myeloma, AML, CLL, ALL, lymphoma, MDS and MPNs.

SOHO Italy 2020 Virtual Meeting

VJHemOnc is proud to present the SOHO Italy 2020 Virtual Meeting, which took place on the 22nd-24th of September 2020.

ERIC 2020 Presentations

VJHemOnc was official Media Partner for the ERIC 2020 Virtual Meeting, New Frontiers in CLL Research, which took place on 1-3…

FDA clears first in vitro diagnostic MRD assay for CLL

The U.S. Food and Drug Administration (FDA) has approved the first and only assay – clonoSEQ®, to screen and assess…

EHA 2020 Top Picks

VJHemOnc are excited to present late-breaking abstracts and key trial updates announced at this year’s virtual EHA meeting!

FDA approve ibrutinib and rituximab combination for CLL

Following positive results gleaned from the E1912 trial (NCT02048813), the U.S. Food and Drug Administration (FDA) has expanded the indication…

The impact of genetic mutations on the performance of anti-CD19 CAR T-cells in CLL

Chimeric antigen receptor T-cell (CAR-T) therapies have proven particularly successful in hematological malignancies. However, CAR T-cells still underperform when used…

features: Chronic Lymphocytic Leukemia